ePrints

Correction to: A roadmap for clinical trials in MASH-related compensated cirrhosis (Nature Reviews Gastroenterology & Hepatology, (2024), 10.1038/s41575-024-00955-8)

Lookup NU author(s): Professor Quentin AnsteeORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© Springer Nature Limited 2024.Correction to: Nature Reviews Gastroenterology & Hepatologyhttps://doi.org/10.1038/s41575-024-00955-8, published online 17 July 2024. In the version of the article initially published, the reference Chalasani, N. et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterol. 158 1334–1345 (2020) was missing and has now been added as ref. 111 in the second paragraph of the “HVPG as a surrogate end point” section. Additionally, in the second paragraph of the “Current scenario of clinical trials in MASH” section, the sentence “NAVIGATE (NCT04365868; 357 participants) was a phase IIb–III trial…” has been corrected to “NAVIGATE (NCT04365868; 357 participants) is a phase IIb–III trial…”. These corrections have been made to the HTML and PDF versions of the article.

Publication metadata

Author(s): Pericas JM, Anstee QM, Augustin S, Bataller R, Berzigotti A, Ciudin A, Francque S, Abraldes JG, Hernandez-Gea V, Pons M, Reiberger T, Rowe IA, Rydqvist P, Schabel E, Tacke F, Tsochatzis EA, Genesca J

Publication type: Note

Publication status: Published

Journal: Nature Reviews Gastroenterology and Hepatology

Year: 2024

Volume: 21

Print publication date: 01/11/2024

Online publication date: 05/08/2024

Acceptance date: 02/04/2024

ISSN (print): 1759-5045

ISSN (electronic): 1759-5053

Publisher: Nature Research

URL: https://doi.org/10.1038/s41575-024-00976-3

DOI: 10.1038/s41575-024-00976-3

Share